Cresco Spine earned FDA 510(k) clearance for its spring distraction system, the company said in a Jan. 19 LinkedIn post.
The SDS implant is designed for addressing early onset scoliosis, and it previously earned the FDA’s Breakthrough Device Designation.
Cresco Spine plans a controlled release of SDS in the U.S. and Canada.
At the Becker’s 32nd Annual Meeting: The Business and Operations of ASCs, taking place October 29-31 in Chicago, ASC leaders, surgeons and healthcare executives will explore strategies to drive growth, enhance operational performance, navigate reimbursement challenges and prepare for the future of ambulatory surgery. Apply for complimentary registration now.
